Ask AI
ProCE Banner Activity

A New Treatment Option for People With Schizophrenia

Clinical Thought

A novel mechanism of action focused on muscarinic receptors represents a groundbreaking development in the schizophrenia treatment landscape, offering an entirely new approach to managing this debilitating disease. This commentary describes in detail a new combination utilizing a muscarinic receptor agonist and a peripheral muscarinic antagonist. This combination reduces dopamine release without blocking dopamine receptors, thereby avoiding common side effects of traditional antipsychotics. This novel approach signifies a major shift from the dopamine receptor blockade strategy used for the past 70 years.

Released: March 27, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Leslie Citrome, MD, MPH: consultant: AbbVie, Acadia, AdhereTech, Alkermes, Altus, Alumis, Arc, Auritec, Autobahn, Avant Healthcare Solutions, Axsome, Biogen, BioXcel, Bristol Myers Squibb/Karuna, Boehringer Ingelheim, Cadent, Cerevel, Clario/Medavante/Prophase, Clinilabs, Compass, Corcept, Definium, Delpor, Eisai, Enteris BioPharma, Health Wellness Partners, HLS Therapeutics, Idorsia, INmune Bio, Intra-Cellular, Johnson & Johnson/Janssen, Little Bear, Lundbeck, Luye, Lyndra, MapLight, Marvin, Mindmed, Neumora, Neurocrine, Neurelis, Neushen, Noema, Novartis, Noven, Orexo, Otsuka, Ovid, Pontifax/Draig, Praxis, PSL, Real Chemistry, Relmada, Renew Research, Response, Reviva, Sage, Seaport, Sumitomo/Sunovion, Supernus, Teva, Vanda; speaker: AbbVie, Acadia, Alkermes, Bristol Myers Squibb, Eisai, Idorsia, Intra-Cellular, Johnson & Johnson/Janssen, Lundbeck, Luye, Neopharm, Neurocrine, Noven, Otsuka, Recordati, Takeda, Teva, Vanda; individual publicly traded stock/stock options: Reviva.